Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity

v3.23.1
Stockholders' Equity
12 Months Ended
Jan. 31, 2023
Equity [Abstract]  
Stockholders' Equity
9.
Stockholders’ Equity

Preferred Stock Authorization

The Board is authorized to issue from time to time up to an aggregate of 5,000,000 shares of preferred stock, in one or more series. Each such series of preferred stock shall have the number of shares, designations, preferences, voting powers, qualifications and special or relative rights or privileges to be determined by the Board, including dividend rights, voting rights, redemption rights and sinking fund provisions, liquidation preferences, conversion rights and preemptive rights. No preferred stock has been issued as of January 31, 2023.

Equity Plans

Compensation and Incentive Plans

The Company’s Second Amended and Restated 2011 Compensation and Incentive Plan (the “2011 Plan”) provided for the grant of incentive stock options (“ISOs”), nonqualified stock options (“NQs”), RSUs, DSUs and PSUs and other equity based non-stock option awards as determined by the plan administrator to its officers, employees, consultants and directors. The 2011 Plan expired on July 20, 2021.

The Company’s 2021 Compensation and Incentive Plan (the “2021 Plan”) was proposed by the Board and adopted by the Company’s stockholders in July 2021 to permit the continued issuance of equity-based compensation, including the granting of ISOs, NQs, restricted stock, RSUs, DSUs, PSUs, and other equity based non-stock option awards as determined by the plan administrator to officers, employees, consultants and directors. Under the 2021 Plan, the Company may satisfy awards upon the exercise of stock options or the vesting of stock units with newly issued shares or treasury shares. The Board, or a committee of independent members of the Board (the “Committee”), is responsible for the administration of the 2021 Plan and determining the terms of each award, award exercise price, the number of shares for which each award is granted and the rate at which each award vests. In certain instances, the Board or Committee may elect to modify the terms of an award.

Nonemployee members of the Board may elect to receive DSUs or stock options in lieu of RSUs. The number of units subject to the DSUs is determined as of the grant date and shall fully vest one year from the grant date. The shares underlying the DSUs are not issued until the earlier of the director ceasing to be a member of the Board (provided such time is subsequent to the first day of the succeeding fiscal year) or immediately prior to a change in control.

Option awards may be granted at an exercise price per share of not less than 100% of the fair market value per common share on the date of the grant and not less than 110% of the fair market value per common share on the date of the grant with respect to ISOs granted to employees owning stock possessing more than 10% of the total combined voting power of all classes of stock of the Company. Option awards granted under the 2021 Plan generally vest over a period of one to three years and expire ten years from the date of the grant.

Following Board approval and recommendation, on August 5, 2022 the Company’s stockholders voted in favor of changes to the 2021 Plan (the “Amended and Restated 2021 Plan”). The purpose of the Amended and Restated 2021 Plan is to provide equity and cash incentives to the employees of the Company in order to attract, motivate and retain qualified employees. Changes made to the Amended and Restated 2021 Plan include the addition of 3,000,000 new shares authorized for issuance under the Amended and Restated 2021 Plan and the inclusion of additional methods to satisfy the tax obligations that arise for granted equity awards. The number of shares authorized for issuance under the Amended and Restated 2021 Plan at January 31, 2023 is 7,896,878, including 2,396,878 shares awarded under the 2011 Plan that may become available for issuance under the 2021 Plan due to the expiration, termination, surrender, or forfeiture of such outstanding awards. As of January 31, 2023, there were 2,738,626 shares available for future grants.

The Company has a Long-Term Incentive Program, adopted in fiscal 2016, under which the named executive officers and other key employees may receive long-term equity-based incentive awards, which are intended to align the interests of named executive officers and other key employees with the long-term interests of stockholders and to emphasize and reinforce the Company’s focus on team success. Long-term equity-based incentive compensation awards are made in the form of stock options, RSUs and PSUs subject to vesting based in part on the extent to which employment continues under the Amended and Restated 2021 Plan.

2015 Employee Stock Purchase Plan

Under the Company’s 2015 Employee Stock Purchase Plan (the “ESPP”), six-month offering periods begin on October 1 and April 1 of each year during which eligible employees may elect to purchase shares of common stock according to the terms of the offering. On each purchase date, eligible employees can purchase the Company's stock at a price per share equal to 85% of the closing price of the Company’s common stock on the exercise date, but no less than par value. The maximum number of shares of the Company's common stock authorized for sale under the ESPP is 1,150,000 shares, of which 1,075,024 remain available under the ESPP as of January 31, 2023. There were no shares purchased under the ESPP during the years ended January 31, 2023 and 2022 as the Company suspended the ESPP as of April 1, 2020 and is still evaluating when the suspension will be lifted, if at all.

Stock Option Valuation

The Company measures the fair value of service-based options using the Black-Scholes option-pricing model. Key input assumptions used to estimate the fair value of stock options include the exercise price, the expected option term, the risk-free interest rate over the option’s expected term, the expected annual dividend yield and the expected stock price volatility. The expected option term is determined using the “simplified” method for “plain vanilla” options. The expected stock price volatility is established using the historical volatility of the Company’s common stock over a period of time equal to the expected term of the stock option. The risk-free interest rate is based upon the U.S. treasury bond yield at the grant date, using a remaining term equal to the expected life. The expected dividend yield is 0%, as the Company has not paid cash dividends on its common stock since the Company’s inception.

The Company measures the fair value of performance-based options using the same Black-Scholes option-pricing model key assumptions as the Company’s service-based options with the exception of the expected term. The contractual term is instead used when valuing performance-based options as these options are not “plain vanilla.”

The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted for the fiscal year ended January 31, 2022. There were no stock options granted in the fiscal year ended January 31, 2023.

 

 

 

 

 

For the Fiscal Year
 Ended January 31,
 2022

 

Risk-free interest rate

 

 

 

 

0.9

%

Expected volatility

 

 

 

 

55.8

%

Expected dividend yield

 

 

 

 

0.0

%

Expected term (in years)

 

 

 

6.4

 

The weighted average grant-date fair values of stock options granted during the year ended January 31, 2022 was $0.64 per share.

Stock Option Activity

The following table summarizes the Company’s stock option activity:

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

Weighted

 

 

Average

 

 

 

 

 

 

 

 

 

Average

 

 

Remaining

 

 

Aggregate

 

 

 

Number of

 

 

Exercise

 

 

Contractual

 

 

Intrinsic

 

 

 

Shares

 

 

Price

 

 

Term

 

 

Value

 

Outstanding as of January 31, 2022

 

 

1,263,340

 

 

$

1.40

 

 

 

8.67

 

 

$

 

Granted

 

 

-

 

 

 

-

 

 

 

 

 

 

 

Exercised

 

 

-

 

 

 

-

 

 

 

 

 

 

 

Forfeited

 

 

(538,756

)

 

 

1.67

 

 

 

 

 

 

 

Outstanding as of January 31, 2023

 

 

724,584

 

 

$

1.21

 

 

 

8.05

 

 

$

 

Vested and expected to vest as of January 31, 2023

 

 

703,751

 

 

$

1.20

 

 

 

8.04

 

 

$

 

Options exercisable as of January 31, 2023

 

 

397,083

 

 

$

1.27

 

 

 

7.84

 

 

$

 

Stock Units

The Company has granted RSUs and DSUs with service-based vesting criteria that generally vest over one to three years and has granted PSUs with both market-based and performance-based vesting criteria. In fiscal 2023, the Company granted 1,819,405 RSUs. In addition, in fiscal 2023 the Company granted 740,000 market-based PSUs to certain officers in connection with their appointment. The PSUs will vest on the attainment of a closing share price of $2.50 that is held for twenty consecutive trading days within three years from the grant date. In the event of a change in control of the Company, the vesting of the PSUs is based on the employee's time of service from the grant date.

In fiscal 2022, the Company granted 86,957 DSUs and 1,449,047 RSUs. In fiscal 2022, the Company also granted 300,000 PSUs, which vest over a three-year period in twelve equal quarterly tranches upon the achievement of certain Company-specific goals.

The following table summarizes the Company’s RSU and DSU activity:

 

 

 

 

 

 

Weighted Average

 

 

 

 

 

 

Grant-Date

 

 

 

Number of Shares

 

 

Fair Value

 

Unvested balance as of January 31, 2022

 

 

1,412,691

 

 

$

1.20

 

Granted

 

 

1,819,405

 

 

 

0.51

 

Vested

 

 

(951,274

)

 

 

1.24

 

Forfeited

 

 

(60,000

)

 

 

0.43

 

Unvested balance as of January 31, 2023

 

 

2,220,822

 

 

$

0.64

 

The following table summarizes the Company’s PSU activity:

 

 

 

 

 

Weighted Average

 

 

 

 

 

 

Grant-Date

 

 

 

Number of Shares

 

 

Fair Value

 

Unvested balance as of January 31, 2022

 

 

317,857

 

 

$

1.10

 

Granted

 

 

740,000

 

 

 

0.21

 

Vested

 

 

(87,500

)

 

 

1.08

 

Forfeited

 

 

(115,357

)

 

 

0.68

 

Unvested balance as of January 31, 2023

 

 

855,000

 

 

$

0.39

 

 

Stock-Based Compensation

The Company recognized stock-based compensation expense within the consolidated statements of operations and comprehensive loss as follows:

 

 

For the Fiscal Years
Ended January 31,

 

 

 

2023

 

 

2022

 

 

 

(Amounts in thousands)

 

Cost of revenue

 

$

42

 

 

$

35

 

Research and development

 

 

34

 

 

 

(77

)

Sales and marketing

 

 

157

 

 

 

114

 

General and administrative

 

 

768

 

 

 

1,618

 

 

 

$

1,001

 

 

$

1,690

 

As of January 31, 2023, unrecognized stock-based compensation expense related to (i) unvested stock options was approximately $0.1 million, which is expected to be recognized over a weighted average period of 1.2 years, (ii) unvested RSUs and DSUs was $0.9 million, which is expected to be recognized over a weighted average amortization period of 1.8 years, and (iii) unvested PSUs was $0.1 million, which is expected to be recognized over a weighted average amortization period of 1.4 years.

Tax Benefits Preservation Plan

On March 4, 2019, the Company entered into the Tax Benefits Preservation Plan in the form of a stockholder rights agreement (“Rights Agreement”) and issued a dividend of one preferred share purchase right (a “Right”) for each share of common stock payable on March 15, 2019 to the stockholders of record of such shares on that date. The Rights expired on March 4, 2022.